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SUMMARY 
Bayesian methods are potentially useful for the design, monitoring, and analysis of clinical 
trials. These methods, however, require that prior information be quantified and that the methods 
be robust. This paper describes a method to help quantify beliefs in the form of a prior distribution 
about regression coefficients in a proportional hazards regression model. The method uses dynamic 
graphical displays of probability distributions that can be freehand adjusted. The method was 
developed for, and is applied to, a randomized trial comparing prophylaxes for toxoplasmosis in a 
population of HIV positive individuals. Prior distributions from five AIDS experts are elicited. The 
experts represent a community of consumers of the results of the trial and these prior distributions 
can be used to try to make the monitoring and analy_sis of the trial robust. 
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1 Introduction 
Bayesian approaches to clinical trials, as discussed for example by Spiegelhalter and Freedman 
(1988) and Freedman· and Spiegelhalter (1992), require the specification of a prior distribution. 
In this paper, an AIDS clinical trial comparing potential prophylaxes for toxoplasmosis is used as 
a context to develop and implement methodology to aid in the elicitation of prior distributions. 
Following Kadane (1986), we require that a range of priors be identified that are representative of 
"the community." These will then be used to try to make monitoring and analysis robust. This 
paper focuses on the elicitation part of such an approach and we report on the prior distributions 
of five individuals. Bayesian analysis and monitoring of the trial is reported in Carlin et al (1992). 
First we provide a description of the toxoplasmosis prophylaxis trial and then describe the elic-
itation method based on graphical input and feedback. We then summarize what we learned from 
eliciting the prior distributions, the results of the trial, and some of the problems in implementing 
a Bayesian approach. 
2 The toxoplasmosis prophylaxis trial 
The toxoplasmosis prophylaxis trial, conducted through the Community Programs for Clinical 
Research on AIDS, was a placebo controlled, modified double blind study to evaluate the effec-
tiveness of both clindamycin and pyrimethamine on the subsequent development of toxoplasmosis 
encephalitis (TE). An effective prophylactic agent needed to be found, since TE was a major cause 
of mortality and morbidity among patients with AIDS, and had been reported to be a very common 
opportunistic infection and was the most common cause of intracerebral mass lesions. 
All patients entered into the study had a positive titer for Toxoplasma gondii. Enrollment was 
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planned for one year with all patients to be followed for a minimum of two years so that the average 
period of follow-up would be two and a half years. A computerized literature search for information 
on toxoplasmosis and AIDS yielded very little, the exception being a paper by Grant et al (1990) 
in which it was estimated that 30% of the placebo patients would develop TE in two and a half 
years. 
The study had four treatment groups: active clindamycin, placebo clindamycin, active pyrimeth-
amine, and placebo pyrimethamine with an allocation ratio of 2:1:2:1 respectively. Randomization 
was set up so that allocation to clindamycin and pyrimethamine was unblinded and allocation within 
each group to active or placebo was double blind. The planned analysis was a semi-parametric 
proportional hazards regression model (Cox, 1972). Death was to be treated as a censoring event. 
In order to calculate sample size, based on frequentist methods for computing power, the protocol 
committee agreed upon values for the effects. They assumed that among fully compliant patients 
those on active drug would have a 50% lower rate of TE compared to the pooled placebo groups. 
Given the potential for toxicities, investigators felt that a large reduction in TE, perhaps as high 
as 50%, was necessary before these drugs could be recommended for routine use in the community. 
It was also predicted that 10% of the placebo patients would switch over to one of the active drugs, 
25% of the patients assigned to active drug would not comply with their assignments, and 33% 
of the patients would be lost to follow-up due to death unrelated to treatment assignment. The 
planned sample size was 750 patients with 250 patients to be allocated to each active medication 
group and 125 patients to each placebo group. In the analysis the two placebo groups would be 
combined. 
The first patient was randomized in September 1990. In March of 1991, the active and placebo 
clindamycin groups were terminated due to an excess of non-life threatening but serious toxicities 
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that re~ulted in permanent medication discontinuances. The details of the toxicities are reported in 
Jacobson et al (1992a). The pyrimethamine arm continued. After termination of the clindamycin 
arm, people on either clindamycin or placebo for clindamycin were offered rerandomization to either 
the pyrimethamine group or placebo group with a two to one allocation ratio. 
In April 1992, the trial was terminated because the rate of TE in the pyrimethamine and placebo 
groups was much lower than expected. The rate in the pyrim.ethamine arm was actually slightly 
higher than in the placebo arm, but the difference was not significant and continuation of the trial 
was very unlikely to lead to a significant difference. Data that accrued after termination indicated 
an increased death rate on the pyrimethamine arm; (see Jacobson et al, 1992b). 
3 The survival model and Bayes structure 
The protocol specified an analysis by a proportional hazards model, with a nonparametric un-
derlying hazard function. Our Bayesian analysis will follow this same general approach using the 
partial likelihood as a likelihood. This strategy can be justified using arguments given in Kalbfleisch 
(1978), if a Dirichlet process or a gamma process is used for the underlying hazard. 
Specification of an informative prior distribution is difficult. Methods for specifying opinions 
have been developed for several different sampling models, for example the Bernoulli process (Win-
kler, 1967; Chaloner and Duncan, 1983) and the no~al linear model (Kadane et al., 1980; Garth-
waite and Dickey, 1990 and 1991 ). There are no specific methods that we know of, however, for 
specifying a prior distribution on the regression coefficients of a proportional hazards model. Meth-
ods for other models typically require the expert to specify certain properties of his or her beliefs 
and a distribution is chosen that has these properties, or properties very close to the ones provided 
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by the expert. The distribution is usually chosen from a. specific parametric family, typically a 
conjugate family. Freedman and Spiegelhalter (1983) ta.ke a different approach and specify a. prior 
distribution which is uniform over intervals, see also Spiegelhalter, Freedman and Parmar (1992). 
We chose to take a. combination of these approaches by starting with the specification of a 
prior distribution from a parametric family. The expert then has the option of ma.king freehand 
adjustments. Specifying both the initial parametric distribution a.nd the nonparametric distribution 
a.re done with the help of dynamic graphical plots to provide feedback within the XLISP-STAT 
environment of Tierney (1990). 
4 Elicitation method 
First we describe a method for specifying a parametric prior distribution on the two regression 
parameters corresponding to the two treatment effects, and then discuss freehand adjustments. 
Since the clindamycin a.rm was terminated early, due to toxicities, the method was converted to 
one for a single regression parameter. The univariate method is described in Section 4.3. 
4.1 The bivariate version 
Rather than direct assessment of the proportional hazards regression parameters the elicitation 
scheme is based on three potentially observable quantities, Po, PO, a.nd PP, the probabilities of 
experiencing the toxoplasmosis endpoint within the first two yea.rs of treatment on the placebo, 
clinda.mycin a.nd pyrimetha.mine respectively. The expert can think a.bout ea.ch probability as 
a proportion of a large group of patients, thus incorporating beliefs about noncompliance and 
switchover directly rather than having to consider a perfectly compliant patient ( as in Freedman 
and Spiegelhalter, 1983). Using such potentially observable quantities follows the argument of 
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Kadane et al (1980) that observable quantities are easier to think about than regression parameters. 
The baseline hazard for the placebo is assumed to be the same for each respective treatment 
arm. In the proportional hazards model, we denote the baseline survivor function for the combined 
placebo arms by S(t) and the regression coefficients for the two treatments by {3p and f3c. For 
two-year follow-up: 
Po = 1- S(2) 
pp = 1 - S(2)exp(Pp) 
PC = 1- S(2rxp(Pc). 
In our experience, clinicians consider the efficacy of a treatment as a relative risk reduction 
condition~ on the underlying placebo rate. For example, if the incidence of toxoplasmosis for the 
placebo group over two years is known to be 15%, then the incidence for the pyrimethamine group 
might be thought most likely to be 10%; whereas if it became known that the incidence on placebo 
was in fact 30%, the incidence on pyrimethamine might be thought most likely to be 20%. In both 
cases the relative risk is approximately 0.67. 
Based on these considerations the elicitation scheme asks the expert for a "best guess" of the 
incidence on placebo, denoted by f,0 • The joint probability distribution of pp and pc is elicited 
conditional on p0 = f,0 • To structure a parametric approach we utilize the property that for the 
proportional hazards model, the complementary log-log transformation of pp and Pc has a range 
of the whole real line and is linear in the regression coefficients. Specifically, 
log{-log(l - pp)} = {3p + log{-log(l - Po)} 
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log{- log(l - po)} = .Bo+ log{-log(l - Po)}. 
We use a parametric bivariate distribution for ,8p and /Jo conditional on Po= j,0 , and we assume: 
f({Jp,,8olPo =Po)= f(,8p,,8o). (1) 
To check assumptions, the elicitation process can be repeated using a different follow-up in-
terval and the elicited distributions o~ the /j's can be compared. Under the proportional hazards 
assumption the prior distribution should not depend on the interval. In our example, we repeat 
the process by asking the expert about predictions for both two and three years of follow-up and 
compare the distributions on the regression coefficients. 
4.2 The parametric bivariate distribution 
Although it seems natural to use a bivariate normal distribution for (f3p, .Be), this choice is not 
particularly helpful. For this distribution on the fJ's, the corresponding distribution of pp and Po 
can have singularities at zero and one (Meinhold and Singpurwalla, 1987). Realistic prior opinipns 
on the probabilities are unlikely to have such singularities. We therefore take (,8p, .Bo) to have a 
Type B bivariate extreme value distribution as given in Johnson and Kotz (1972, pp. 251-255), 
f(x, Yim) = em(z+y)(emz + emy)-2+1/m 
x{m _ 1 + (emz + emy)tlm}exp[-(emz + emy)t/m] 
form~ 1. Note that m = 1 corresponds to independence of f3p and /Jo (and therefore of pp and 
Pc) and m > 1 produces positive correlation. For a distribution with location parameters µp and 
µc and scale parameters C1p and C1c the probability density function is obtained by substituting 
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u;1 ( x - µp) for x and u01 (y - µo) for y in the above expression and multiplying the result by 
u;1u01• Marginal distributions are extreme value with scale and lo~ation parameters (µp, up) and 
(µo,uo). 
The marginal distribution of pp has probability density function: 
,. 1 log{-log(l - pp)} - µp 
f(pplµp,ap,po =Po)= (l - pp){-log(l - pp)}up exp{-ezp[ up ]}. (2) 
The corresponding distribution of [-l~g(l - pp)) is Weibull and of course, log[-log(l - pp)] is 
extreme value. 
To specify the distribution on pp and po the expert specifies the upper and lower quartiles for 
pp and po. These quartiles are used to calculate initial values for µp, µo, up, and uc. Starting 
with m = 1, i.e. independence, the expert is presented with plots of each marginal distribution 
and a dialog box with five sliders. The first four sliders adjust the four parameters µp, µo, up 
and uo. As the values are changed, the plots change accordingly. The sliders allow the expert to 
adjust interactively the specified values and see the consequences directly, in terms of the marginal 
distributions for pp and Po. 
The quantities pp and po are likely to be dependent with a positive correlation. Our current 
approach does not address negative correlation. To pick an initial value of m, the expert specifies 
the probability that both probabilities pp and Po are larger than their respective marginal medians. 
If pp and Pc are independent, this probability is 0.25. For the type B extreme valu~ distribution 
the probability is (½)21'm (Johnson and Kotz 1972, p. 253) and the probability must be between 
0.25 and 0.50. 
The parameter m can be adjusted using the fifth slider. Graphical feedback on the joint dis-
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tribution is provided by a contour plot of the joint prior distribution of pp and Pc with regions 
corresponding to approximate 20%, 40%, 60% and 80% density regions based on a chi-square 
approximation to the log likelihood. Changing the value of m does not change the marginal distri-
butions but it does change the contour plot. 
Figure 1 shows the screen of the workstation running the program to elicit a parametric ap-
proximation to a prior opinion. The figure shows the two marginals, a contour plot of the joint 
density and the dialog box with the five sliders. 
The single expert on whom this bivariate method was tried reported that his beliefs were repre-
sented by this parametric family. Methods are being developed for extending this scheme to allow 
for non-parametric adjustments using more general copula combinations of marginal distributions 
(see eg. Shih, 1990). 
4.3 The univariate version 
The univariate version of the elicitation method is very similar to but more flexible than the 
bivariate version. The expert specifies the distribution of pp by first specifying quartiles and then 
adjusting interactively within the parametric family given by Equation 2. Only two sliders are 
required, one for each of µp and qp. The expert subsequently adjusts the plot by freehand using 
a mouse. 
5 Experience with prior elicitation 
The elicitation process has been used with five individuals with quite different backgrounds whom 
we will refer to as A, B, C, D and E. A, Band Care physicians: A practices at a university AIDS 
clinic, B specializes in the neurological manifestations of AIDS and HIV infection, and C practices 
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at a community clinic. D and E are non-physicians involved in research in AIDS clinical trials: D 
manages studies and E is an infectious disease epidemiologist. 
In eliciting the opinions we used a written script so that questions were asked in a standard 
form. 
5.1 Bivariate elicitation 
Expert A provided bivariate information before the clindamycin arm was terminated. The other 
individuals provided opinions after this time and only gave their beliefs -about the effect of pyri-
methamine. 
The initial step requires a best guess value of po. Expert A experienced difficulty in treating 
death without TE as an uninformative censoring event. Expert A decided to partition the popula-
tion into four groups: people who will die without experiencing TE, people who die from an initial 
attack of TE, people who experience TE and recover from the first attack and people who do not 
die and also do not experience TE. A's best ·guess for a large group of patients is given in Table 1 
for the placebo group and the clindamycin group. The increased incidence of death from non-TE 
causes in the treatment group in Table 1 results from reducing the risk of TE and thus allowing 
other clinical events to cause death. Expert A could not agree with treating death from non-TE 
related causes as uninformative censoring. 
In light of this we proceeded to elicit A's opinion using the combined endpoint of death or TE. 
A's best guess was j,0 = 0.69. Conditional upon this, A specified initial values for the mode, 25th 
percentile and 75th percentile for the distribution of pc: 0.60, 0.40 and 0.80 respectively. A adjusted 
the plot derived from these initial values ending up with µc = -0.15 and qc = 0.25. We then 
discussed the pyrimethamine treatment effect. Expert A believed that the marginal distribution 
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was essentially equal to that for clindam.ycin. 
Following the script, we explained the idea behind the joint probability that both proportions 
would be above their medians and A reported a joint probability of 0.45 ( this corresponds to 
strong dependence). Figure· I shows the distribution specified by this physician as displayed on the 
workstation screen. Expert A found the plots extremely helpful and suggested some modifications 
to the program. 
5.2 Univariate elicitation 
The remaining four experts specified their beliefs using the univariate version of the method for pp. 
None of these individuals had the difficulty experienced by A of treating death as uninformative 
censoring. Each individual had a very different approach to answering. the questions. 
Experts B, C and E had no difficulty providing initial quartiles and a probability distribution 
with the process completed in about 30 minutes. Expert D took much longer, over an hour. and 
needed to make several side calculations and assumptions about patient attributes. Specifically, D 
assumed that among the patient population CD4 counts were approximately uniformly distributed 
below 200. Other factors that influenced D were that the treatment could have some efficacy in 
preventing other opportunistic infections such as Pneumocystis carinii pneumonia (PCP). 
The values of p0 for B, C, D and E were 0.20, O. 75, 0.18 and 0.65 respectively. The four 
distributions elicited are given in Figure 2, along with the expert A's marginal distribution for pp. 
The elicited distributions were graphs of a density function, corresponding to a continuous 
distribution. Each graph was stored using a 32 point representation with uniformly spaced points 
on the x-axis. This was converted to a 31 point discrete approximation with equal probability at 
each point, not necessarily. equally spaced. The approximation is based on a linearly interpolation 
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of the 32 point representation. 
5.3 Distributions on the regression coefficient 
The distributions on the regression coefficient, /jp, were calculated from the discrete approximation. 
The distributions on /jp for all five experts are given in Figure 3 as probability histograms. Recall 
that the distribution for A corresponds to a different endpoint than that considered by the other 
four. 
5.4 Checking assumptions 
In the elicitation process we as~umed that the proportional hazards model holds, that the prior 
distribution on the regression coefficients are independent of that on the underlying hazard and 
that the independence assumption in Equation 1 holds. To check the assumptions the process was 
repeated for three experts by asking about three year in addition to two year predictions~ The 
elicited distributions on /jp for C, D, and E are shown in Figure 4. Clearly the assumptions do 
not hold as the distributions are not sufficiently close. Further research is necessary to address this 
issue. 
6 Discussion 
6.1 Lesons · learned about the elicitation process 
Through this experiment in elicitation we !_earned that: 
1. The dynamic graphical displays did help the experts to visualize probability distributions and 
they did provide useful instant feedback. 
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2. A written script was developed, and improved upon after the first session, to give clarity and 
consistency to the questions asked. Having a. clear well defined outline questions to ask of the 
expert was extremely important. 
3. Experts a.re very different both in terms of opinions and how they parse the problem. What 
was easy for one expert was hard for another. Developing a single method for elicitation that 
is good for everybody will be difficult, if not impossible. 
4. Even though the process only requires specification of a best guess value for po experts wanted 
to report their uncertainty a.bout it. 
5. Extreme percentiles may be better than quartiles. Several experts started from "95% inter-
vals" when asked for their quartiles. The 2.5th and 97 .5th percentiles may therefore be easier 
for them to think a.bout, as approximate bounds, than the 25th and 75th. 
6. A satisfactory endpoint is essential but ma.y be difficult to decide upon without exploring the 
data. 
7. Some check of the proportional hazards and other assumptions is required. The distributions 
obtained from asking a.bout three year predictions were different from those obtained from 
two yea.r predictions. 
In summary this elicitation process is not perfect, but it is a. first attempt to develop a method. 
6.2 Lessons learned about the toxoplasmosis trial 
At the completion of the trial we learned: 
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1. None of the experts predicted the very low rate of TE experienced in the trial. Out of the 
396 people in the trial only 12 out of 264 on pyrimethamine got TE and only 4 out of 132 on 
placebo got TE. The low rate is believed to be partly due to the prophylaxis treatment for 
PCP. All patients were taking some drug as PCP prophylaxis throughout the trial. Among 
patients receiving the drug Bactrim, TE was extremely rare and so Bactrim may also have 
a prophylactic effect for TE in addition to PCP. During the time the trial wa.s running, 
other studies indicated that Ba.ctrim may be an effective PCP prophylaxis and many patients 
switched to Ba.ctrim during the trial. 
2. All five experts put high probability on a large beneficial effect of the treatment. They were 
wrong and the rate of TE wa.s slightly higher in the pyrimetha.mine group than in the placebo 
group. 
3. In the pyrimethamine group 46 out of 264 people died compared to only 13 out of 132 in the 
placebo group. The death rate was higher in the pyrimetha.mine group. The data indicated 
that death wa.s informative and the analysis should include death in the endpoint. The 
assumption ma.de by the protocol tea.m at the design stage of the trial that there would be 
no difference in the non TE death rates in the different arms, wa.s wrong. Four of the five 
prior distributions were elicited without death in the endpoint. 
4. Using death or TE a.s a.n endpoint the proportional hazards model did not provide a good 
fit to the data. The hazard for death in the pyrimetha.mine group increased over follow-up 
compared to the placebo group. 
Bactrim becoming the choice for standard prophylaxis for PCP during the trial illustrates that 
standard care for AIDS changes rapidly a.nd might well have changed the outcome of the trial. 
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The changing nature of standard care and the large number of drugs many AIDS patients take 
introduces new challenges to the statistical analysis of an AIDS clinical trial: this is discussed in 
detail in Ellenberg, Finkelstein and Schoenfeld (1992). These challenges are present in either a 
Bayesian or frequentist approach. 
Knowledge about AIDS is changing rapidly. Information is accrued during a trial from sources 
independent of the trial. Experts will accrue information from their clinical practice and elsewhere 
during a trial. In addition, other trials may yield information: trials for PCP prophylaxis and some 
French trials for TE prophylaxis were concurrent with our trial. Information accrued concurrently 
could be incorporated into either the likelihood or the prior distributions. 
In order to specify a prior distribution the model that will be used for analysis must be specified. 
The data may indicate an alternative model. Perhaps one prior distribution and one model could 
be used at the design stage and, subsequently, when the statistician decides on a model of choice 
for an analysis, either interim or the final, the statistician could return to the expert, who remains 
blinded to the data, and elicit a prior distribution for that model. The prior specification of a 
model is also required for a correct frequentist analysis. 
This excercise has illustrated some of the practical problems in implementing a Bayesian ap-
proach to a clinical trial. 
6.3 The need for an elicitation method 
Even if prior distributions are not accepted for analysis and monitoring they are clearly useful in 
the design stage to decide on a sample size, to decide whether or not the trial is feasible and to 
decide on the ethics of the trial. 
In the design of this trial the protocol team used their best guesses for the magnitude of the 
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rates and effects to compute a sample size. The explicit incorporation of prior uncertainty into the 
design process would be beneficial. In addition, at the design stage, if a physician believed that 
an arm of a clinical trial was harmful to a patient then it would be unethical for that physician to 
enroll patients in a trial involving the possible use of that treatment. In this trial the beneficial 
effect of the prophylaxis must b~ large enough to outweigh the potential toxicity and side effects of 
the drug before it would be used routinely. The quantification of prior opinion is required for an 
individual to decide whether it is ethical to participate in the trial: either as a physician or as a 
patient. 
Prior distributions a.re also required for Bayesian monitoring of a trial. ff a treatment is to be 
widely used, the results of a clinical trial must be convincing to many different people: in particular 
to the physicians prescribing it and to the people receiving the treatment. A method for stopping 
a trial could be to stop when a majority of this community of interested parties would agree on 
the practical implications of the results. It is therefore appropriate to elicit prior opinions from as 
many such people as possible in order to determine when to stop the tr~al. 
Such Bayesian monitoring of this trial using such a method is discussed in Carlin et al (1992); 
see also Kadane (1986), Louis (1992), Carlin and Louis (1992). 
6.4 Discussion 
Bayesian methods are becoming increasingly recognized as appropriate for biostatistical problems 
and clinical trials, see for example Breslow (1990). The implementation of Bayesian methods 
requires the specification of prior distributions. Prior distributions are hard to specify, however, 
and little guidance is available in the literature for elicitation in clinical trials. 
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die die recover from alive and 
without TE from TE first TE no TE 
placebo 51% 9% 9% 31% 
clindamycin 54% 3% 3% 40% 
TABLE 1: Expert A's best guesses. 
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Fig 1: the screen for the bivariate el i citation for expert A. 
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Fig 3: prior distributions on the regression coefficient from 2 year probabilities 
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Fig 4: the prior d~stribu~ions on regression coefficient from 3 year probabilities for{:;. D and E 
